Pfizer and BioNTech have submitted a request to the FDA for Emergency Use Authorization of an omicron-adapted COVID-19 booster dose for individuals 12 years of age and older. Pending authorization, the omicron BA.4/BA.5-adapted bivalent vaccine will be available to ship immediately.
Read the full post on Becker's Hospital Review - Healthcare News
